2012 looks a banner year for Teva's Copaxone

Expert: Company to report net profit of $4.74 billion this year.

By NADAV NEUMAN
August 6, 2012 22:32
Teva CEO JEREMY LEVIN

Teva CEO JEREMY LEVIN 370. (photo credit: Reuters)


Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS